What did Pacific Edge Limited announce?
Pacific Edge Limited (NZX: PEB) filed “Pacific Edge 2026 Annual Shareholders Meeting - Results” with NZX on 20 August 2026, as an agm announcement.
- Which company?
- Pacific Edge Limited (NZX: PEB)
- When was it filed?
- 20 August 2026
- Where is the original?
- NZX announcement
Pacific Edge 2026 Annual Shareholders Meeting - Results
20 August 2026
PACIFIC EDGE 2026 ANNUAL SHAREHOLDERS MEETING RESULTS
DUNEDIN, New Zealand – At Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) Annual
Shareholders’ Meeting, held on 20 August 2025, shareholders were asked to vote on six
resolutions, which were supported by the Board.
As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolutions passed by
shareholders were:
• Resolution 1: To authorise the Directors to fix the auditor’s remuneration for the ensuing
year
• Resolution 2: That Bryan Williams, who retires in accordance with NZX Listing Rule 2.7.1
and is eligible for re-election, be re-elected as a Director of the Company
• Resolution 3: That Simon Flood, who retires in accordance with NZX Listing Rule 2.7.1 and
is eligible for election, be elected as a Director of the Company
• Resolution 4: That the payment in cash of $12,699 to Simon Flood, being unpaid Director
remuneration that has accrued to him in respect of the period from 19 December 2025 to 31
March 2026 be approved for all purposes, including NZX Listing Rule 2.11.1
• Resolution 5: That the issue of 152,561,001 Shares under NZX Listing Rule 4.5.1, being
Shares issued under the Placement, Shares issued to certain participants in the Retail Offer,
and Shares issued in consideration for professional services provided in connection with the
Placement and Retail Offer, be approved and ratified for all purposes, including NZX Listing
Rule 4.5.1(c)
• Resolution 6: That the issue of 59,998,716 Shares under NZX Listing Rule 4.3.1(c), being
Shares issued to certain participants in the Retail Offer, be approved and ratified for all
purposes, including paragraph (a) of the definition of “share purchase plan” in the NZX
Listing Rules
RESOLUTION: FOR AGAINST ABSTAIN
1. Auditor’s remuneration
660,399,757
(99.94%)
407,795
(0.06%)
854,630
2. Bryan Williams re-
election
659,295,612
(99.69%)
2,075,767
(0.31%)
290,803
3. Simon Flood election
656,064,772
(99.90%)
665,264
(0.10%)
4,932,146
4. Payment to Simon
Flood
655,195,114
(99.84%)
1,080,582
(0.16%)
803,275
5. Approval of share issue
401,524,695
(99.89%)
458,733
0.11%
48,919,882
6. Issue of shares to
certain participants
610,586,164
(99.84%)
955,326
0.16%
50,120,692
2
As at the commencement of the meeting, Pacific Edge Limited had 1,241,852,687 total number of
voting shares on issue.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +64 22 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in
the development and commercialization of bladder cancer diagnostic and prognostic tests for
patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin,
New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned,
and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with hematuria and those being monitored for recurrent
disease. The tests help improve the overall patient experience, while prioritizing time and clinical
resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South
America. In the US, the test has been used by over 5,000 urologists who have ordered more than
130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public
healthcare and all residents have the option of buying the test online.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.